ERR2598214
fetal · fetal
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- fetal
- cancer_type_detailed
- —
- subtype
- fetal
- cancer_type
- fetal
- subtype
- fetal
- sex
- fetal
- race
- fetal
- fetal_age_hindbrain
- 7
- umap1_2d
- -4.889045428
- umap2_2d
- 3.084923644
- umap1_3d
- -2.495126493
- umap2_3d
- 3.342465565
- umap3_3d
- -1.424768098
- dataset
- fetal
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.530
- E2F_TARGETS+0.490
- HEDGEHOG_SIGNALING+0.440
- PROTEIN_SECRETION+0.410
- MYC_TARGETS_V1+0.400
- MITOTIC_SPINDLE+0.380
- UV_RESPONSE_DN+0.330
- TGF_BETA_SIGNALING+0.320
- PANCREAS_BETA_CELLS+0.290
- MTORC1_SIGNALING+0.280
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.550
- INTERFERON_GAMMA_RESPONSE-0.420
- ALLOGRAFT_REJECTION-0.390
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.380
- MYOGENESIS-0.340
- INFLAMMATORY_RESPONSE-0.330
- MYC_TARGETS_V2-0.310
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.300
- APICAL_JUNCTION-0.270
- IL6_JAK_STAT3_SIGNALING-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598208 | fetal | fetal | 0.886 |
| 2 | ERR2598196 | fetal | fetal | 0.873 |
| 3 | ERR2598213 | fetal | fetal | 0.865 |
| 4 | ERR2598198 | fetal | fetal | 0.851 |
| 5 | ERR2598094 | fetal | fetal | 0.838 |
| 6 | TCGA-BH-A204-01A-11R-A157-07 | — | B | 0.812 |
| 7 | TCGA-E9-A1N9-01A-11R-A14D-07 | — | C | 0.809 |
| 8 | SRR26320082 | — | — | 0.802 |
| 9 | R322R | — | — | 0.801 |
| 10 | MDT-AP-3327 | Med | Medulloblastoma | 0.800 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.530 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.490 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.440 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.410 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.380 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.330 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.320 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.290 | Cobimetinib | — uncovered |
| MTORC1_SIGNALING | 0.280 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.260 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.250 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.160 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.110 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.050 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.040 | Inavolisib | — uncovered |